GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Pre-Tax Income

Contineum Therapeutics (Contineum Therapeutics) Pre-Tax Income : $-16.35 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Contineum Therapeutics's pretax income for the three months ended in Mar. 2024 was $-8.42 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-16.35 Mil. Contineum Therapeutics's pretax margin was %.

During the past 3 years, Contineum Therapeutics's highest Pretax Margin was 46.34%. The lowest was 46.34%. And the median was 46.34%.

Contineum Therapeutics Pre-Tax Income Historical Data

The historical data trend for Contineum Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Pre-Tax Income Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Pre-Tax Income
-29.00 -24.25 23.17

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial -7.51 -4.82 - -7.93 -8.42

Competitive Comparison of Contineum Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Contineum Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Pre-Tax Income falls into.


Contineum Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Contineum Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=16.077+2.695+-0.208+4.606+0
=23.17

Contineum Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-9.93+-0.123+0+1.636+0
=-8.42

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics  (NAS:CTNM) Pre-Tax Income Explanation

Contineum Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-8.417/0
=%

During the past 3 years, Contineum Therapeutics's highest Pretax Margin was 46.34%. The lowest was 46.34%. And the median was 46.34%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Pre-Tax Income
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024